Shares of SELLAS Life Sciences Group (NASDAQ: SLS) plunged nearly 20% in overnight trading after the biotechnology company announced a discounted $150 million share offering. The sell-off came just a day after the stock rallied sharply on positive topline results from its late-stage leukemia vaccine trial. (Sources: TradingView, Yahoo Finance)
ETMarkets.com
2/5
$150 million share sale triggers investor concerns
SELLAS priced its public offering of 11.54 million new shares at $13 apiece, raising approximately $150 million in gross proceeds. The offer price represented a discount of around 28% to the stock's previous closing price of $17.95, triggering concerns over dilution among existing shareholders.
ETMarkets.com
3/5
Additional shares could increase dilution
The company also granted underwriters a 30-day option to purchase up to 1.73 million additional shares at the offering price. If fully exercised, the transaction could generate gross proceeds of approximately $172.5 million. The offering was expected to close on November 20, subject to customary conditions.
ETMarkets.com
4/5
Strong leukemia trial results had sent shares soaring
The latest decline followed a massive rally after SELLAS announced positive topline results from…